



# Report of the Executive Board

## Dear Shareholders and Business Partners,

With its products and solutions for more efficient development and production of medicines and vaccines, Sartorius is directly addressing the third Sustainable Development Goal of the United Nations: “Ensure healthy lives and promote well-being for all at all ages.” Our focus on the biopharmaceutical industry is also one reason why we again performed strongly in 2022 following two exceptionally dynamic years. Sales revenue rose 15 percent in constant currencies to almost 4.2 billion euros, with broad-based growth across our portfolio and all geographies in a challenging environment, and we currently see ourselves as being a good year ahead of our mid-term plan. While growth in the lab division was even slightly stronger than forecast, the bioprocess division was influenced by the expected normalization of demand. At 33.8 percent, the underlying EBITDA margin achieved in 2022 was close to the high prior-year level, even though we saw the expected significant increase in costs.

We continued to substantially invest in new capacities last year and spent more than half a billion euros in capital expenditures, primarily to expand production across all geographies, in particular in Germany, Puerto Rico, the United States, France and China. We also completed three acquisitions that add innovative and complementary products to our portfolio. We expanded our bioanalytics offering by acquiring a majority stake in ALS Automated Lab Solutions and strengthened our downstream business with the purchase of Novasep’s chromatography division. Albumedix adds a critical component for the manufacture of innovative biopharmaceuticals to our portfolio, particularly for modalities such as cell therapies, viral therapies, and vaccines. We also expect the partnership with the BICO Group agreed upon in December to provide valuable input for innovative applications in research and development, for example in the field of 3D cell printing.

Along with the continued expansion and sales revenue growth came an increase in the number of employees by more than 2,100 to around 16,000 at the end of December 2022. In light of the normalizing demand situation, we have adjusted the pace of recruitment, setting the focus on training and fully integrating the many new employees who have joined us, as well as on consolidating our organization and its processes.

Due to the significant political and economic uncertainties, the capital market sentiment was negative overall last year. Shares of growth companies were also burdened by interest rate increases. On top of this, there was a certain level of uncertainty among investors around the short-term growth prospects of biopharma suppliers in the context of the transition into a post-pandemic phase. In light of this challenging environment, the Sartorius preference share ended 2022 at a price of 369.40 euros, down around 38 percent year over year. The ordinary share closed 33 percent lower at 334.50 euros.



In the two previous years, the pandemic had led to high demand from coronavirus vaccine manufacturers. In addition, customers placed their orders earlier and, in some cases, increased their inventories in view of the strained supply chains. In 2022, the expected normalization of demand set in, and Covid-19-related sales revenues experienced significant declines; similarly, some customers have started to reduce their inventories again. We expect the normalization of demand to continue for some time and thus anticipate sales revenue growth in the low single-digit percentage range for the current year. Excluding the Covid-19-related business, the increase should be in the high single-digit range. We aim to maintain our profit margin at around the high prior-year level. The investment level will also remain high; we expect the CAPEX ratio to be around 12.5 percent again in 2023.

The fundamental growth drivers in our markets are fully intact. Demand for biopharmaceuticals is increasing in all indication areas and regions, and at the same time, the biotech industry is in an extraordinarily innovative phase. We are excellently positioned to support our customers in their endeavors and to seize the opportunities that arise from this. Substantial investments in capacities and acquisitions that expand our capabilities will therefore remain part of our growth strategy.

While our basic assessment of medium-term market growth remains unchanged, we have raised our sales revenue forecast for 2025 to around 5.5 billion euros to reflect higher price levels caused by inflation. At the same time, we have confirmed our 2025 profitability expectation of an underlying EBITDA margin of around 34 percent.

The peak phases of the pandemic posed a considerable challenge to everyone. At the same time, our employees experienced what kind of extraordinary challenges we can master as a team. On behalf of the Executive Board, I would like to express my sincere thanks and appreciation for the exceptional performance the global Sartorius team continued to deliver in 2022.

I would also like to sincerely thank you, our valued customers, business partners, and shareholders. The trust you have placed in Sartorius, often for many years, has been a fundamental driver of the company's positive performance. It would be our great pleasure to have you continue to accompany us on our journey in 2023 and beyond.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Joachim Kreuzburg'. The signature is fluid and cursive, written in a professional style.

Dr. Joachim Kreuzburg  
Chief Executive Officer

# Executive Board

The Group's central management entity is the Executive Board of Sartorius AG. It defines the strategy, is responsible for the operational management of the Group and controls the distribution of resources within the organization.

## Joachim Kreuzburg

CEO

Group Strategy, Human Resources, Corporate Research, Legal & Compliance, Communications, Sustainability

Board member since 2002



## Rainer Lehmann

Member of the Board

Finance, Information Technology, Data Management, Corporate Sourcing

Board member since 2017



## René Fáber

Member of the Board

Head of Bioprocess Solutions

Board member since 2019



## Gerry Mackay

Member of the Board

Head of Lab Products & Services

Board member since 2019



# Report of the Supervisory Board

## Dear Shareholders and Business Partners,

Here at Sartorius, we can once again look back on another extremely successful year. With consolidated sales revenue of approximately 4.2 billion euros, the company grew profitably in both divisions, despite demand normalizing after many countries recovered from the COVID-19 pandemic as well as the difficult new challenges posed by a markedly different environment, both geopolitically and macroeconomically.

In 2022, the Supervisory Board intensively dealt with the situation and prospects of the company. We advised the Executive Board on corporate management and performed the tasks assigned by German corporate law and the company's Articles of Association. The Executive Board informed us regularly by providing prompt and comprehensive reports, both written and verbal, about all relevant corporate planning and strategic development issues, the progress of business in the divisions, the situation of the Group, including its risk situation, risk management and internal control systems, as well as about compliance. The health situation among the workforce and measures to safeguard supply chains and a stable energy supply were also on the agenda. The company's significant transactions were discussed in depth by the respective committees responsible as well as by the full Supervisory Board, on the basis of the reports provided by the Executive Board. Following thorough review of the Executive Board's reports and proposed resolutions, we voted on these to the extent that our vote was required.

Our cooperation with the Executive Board was always characterized by openness, constructive dialogue, and trust.

## Focus of the Supervisory Board's Conferences

The Supervisory Board held six meetings in the reporting year, all six of which were attended by all of its members. Four meetings were held as in-person meetings, and two were held in the form of a videoconference. A list of the participants that attended the Supervisory Board meetings and the meetings of the Supervisory Board committees can be found on the company's website and on page 14 of this report. The Executive Board attended the majority of our meetings; where matters relating to the Executive Board, internal Supervisory Board matters, or selected special topics were discussed, we met to discuss the relevant agenda items without the participation of the Executive Board.

At our meeting on February 10, 2022, we comprehensively discussed the annual and consolidated financial statements for fiscal 2021 and endorsed them based on the reports given by the Audit Committee and the independent auditors who were present during this item of the agenda. After the independent auditors' report and deliberations were held, we also endorsed the Non-Financial Group Statement for the reporting year.



Beyond this, we conferred about and approved the agenda, along with the proposed resolutions, for the 2022 Annual General Meeting, including the proposal for appropriation of the annual profit, as well as the remuneration policy for the Executive Board members. In view of the pandemic that was still ongoing at the time, we decided together with the Executive Board to hold the Annual General Meeting virtually again and conferred in detail regarding how the rights of shareholders, in particular the right to ask questions, could be considered in the best possible way. Corresponding principles were adopted. A discussion of various acquisition opportunities was also on the agenda.

Following the preceding regular elections of employee and shareholder representatives in March 2022, the new Supervisory Board held its first meeting on March 25, 2022 and elected the chair, vice-chair, and members of the committees. Furthermore, in light of the war in Ukraine and its consequences, the company's senior management informed us about various aid measures taken by Sartorius, the restriction of business activities in Russia, and how the company was preparing for a possible energy shortage, especially at its sites in Germany. We also received an overview of various financing matters and, in this context, we approved the conclusion of a new syndicated loan agreement and further loan agreements. Another area of discussion was the involvement of external expertise in the self-assessment of the Supervisory Board's work and in reviewing whether the compensation paid to the Executive Board and Supervisory Board is appropriate.

At our meeting on July 12, 2022, the Executive Board provided us with an overview of the status of various strategic initiatives and projects. Among other projects, the potential acquisition of the British company Albumedix was presented and discussed. We also received a detailed status report on the sustainability strategy and various sustainability initiatives implemented by the company.

At a meeting on August 3, 2022, the Supervisory Board adopted a resolution, after renewed thorough consideration, to approve the acquisition of Albumedix, which will significantly expand the portfolio of the Bioprocess Solutions Division, particularly for applications in advanced therapies.

At a further Supervisory Board meeting on September 15, 2022, which was also attended by a number of senior executives from Business Development, Marketing, and Sales, we discussed corporate strategy issues, potential portfolio additions in both divisions, and selected regional focus topics in detail. In addition, the Executive Board briefed us on matters relating to human resources strategy and employee development and retention programs, as well as succession planning. The results of the Executive Board and Supervisory Board compensation benchmarking were another point of discussion.

At the Supervisory Board meeting on December 8, 2022, we discussed the results of the self-assessment of the Supervisory Board's work and modifications to our Board's competence profile and rules of procedure. We also adopted the Declaration of Compliance for 2022 and discussed recommendations by the Executive Task Committee on the target agreements for the members of the Executive Board in 2023, which were subsequently adopted outside of a meeting in writing. In addition, we discussed matters relating to succession planning on the Executive Board, Executive Board compensation, and selected companies for the peer group

comparison for Executive Board compensation. Beyond this, we obtained information on progress being made with respect to our sustainability strategy and programs. We approved the Executive Board's plan to acquire an equity interest in the Swedish company BICO Group AB in connection with a sales and development partnership. We also approved the budget for 2023, which we had previously discussed in depth.

## Activity Report of the Committees

Four committees support the work of the Supervisory Board. These prepare topics for discussion by the full Supervisory Board and, where permissible, make decisions in individual cases instead of the full Supervisory Board. The committee chairpersons reported regularly to the Supervisory Board on the details of their committee work.

The Executive Task Committee held three meetings in the reporting year, all of which were held in person. Its discussions primarily focused on the company's various strategic actions as well as on Executive Board matters, particularly on preparation of resolutions on Executive Board remuneration. In addition, the committee dealt with the system on promotion of managers, succession planning for selected functions, as well as the topics of risk management and compliance. In addition, the committee conferred on the implementation of various regulatory changes to prepare for the discussions and the resolutions to be taken by the full Supervisory Board.

The Audit Committee held four meetings during the reporting year, two of which were held in person and two in the form of a videoconference. The committee prepared for the full Supervisory Board's conference on endorsement and approval of the consolidated annual financial statements for fiscal 2021 and discussed the quarterly results and the first-half financial report of 2022. Additional focal points were monitoring the effectiveness of the Group-wide risk management and internal control system. The committee also discussed matters relating to Group financing, IT security, and the company's sustainability management.

Beyond these items, the committee reviewed the Internal Auditing Department report, which did not indicate any material discrepancies in business transactions, and also considered the department's plans for the upcoming months. With respect to the audit of the annual financial statements for fiscal 2022, the committee confirmed the independence of the auditors and deliberated in detail on selecting auditors to recommend at the Annual General Meeting for appointment and commissioning to perform an audit review, as well as on defining and monitoring the audit procedure and the focal points of the audit.

The Nomination Committee and Conciliation Committee did not meet in 2022.

**Individual Meeting Attendance of the Supervisory Board Members 2022**

Supervisory Board Member	Meetings	Executive Task	
		Committee	Audit Committee
Lothar Kappich	6/6	3/3	4/4
Manfred Zaffke	6/6	3/3	4/4
Annette Becker	6/6	3/3	--
David Raymond Ebsworth	6/6	--	--
Daniela Favoccia	6/6	--	--
Petra Kirchhoff	6/6	--	--
Dietmar Müller	6/6	--	4/4
Ilke Hildegard Panzer	6/6	--	--
Hermann-Jens Ritzau	6/6	--	--
Klaus Rüdiger Trützschler	6/6	3/3	4/4
Frank Riemensperger (member since March 25, 2022)	5/6	--	--
Sabrina Wirth (member since March 25, 2022)	5/6	--	--
Karoline Kleinschmidt (member until March 25, 2022)	1/6	--	--
Thomas Scheper (member until March 25, 2022)	1/6	--	--

## Training and Further Education Measures

As a matter of principle, the members of the Supervisory Board proactively undertake the training and further education measures required for their duties. To the extent necessary, the company provides organizational support and assumes the costs. When new members join the Board, they are provided extensive documentation to help them familiarize themselves with their new position, and onboarding meetings are also held to familiarize them with the company's business model and organizational structures. During the reporting year, the members of the Audit Committee also attended a training seminar on legal innovations resulting from Germany's Financial Market Integrity Strengthening Act (*Finanzmarktintegritätsstärkungsgesetz*) and on the EU taxonomy.

## Audit of the Annual and Consolidated Financial Statements; Review of the Non-Financial Group Statement

The annual and consolidated financial statements prepared by the Executive Board for fiscal 2022 and the management report of Sartorius AG were reviewed by the independent auditing company KPMG AG Wirtschaftsprüfungsgesellschaft based in Hanover, Germany. This company had been commissioned by the Audit Committee of the Supervisory Board pursuant to the resolution passed at the Annual General Meeting on March 25, 2022. The independent auditors issued an unqualified audit certificate.

The auditors attended the Audit Committee meeting on February 9, 2023, and the Supervisory Board Meeting on February 10, 2023, and reported on the essential results of their audits.

Sufficient time was allotted for discussion of all issues with the auditors. Written information and audit reports had been sent to all Supervisory Board members on time and were discussed in detail during the meetings mentioned. On the basis of its own examination of the annual Sartorius AG and consolidated financial statements, the Sartorius AG management report and the Group management report, the Supervisory Board concurred with the results of the audit conducted by KPMG and, at the meeting on February 10, 2023, endorsed the financial statements of Sartorius AG and the Group on recommendation by the Audit Committee. The annual financial statements were thus approved. The Supervisory Board and the Executive

Board will submit a proposal at the Annual General Meeting on March 29, 2023, to pay dividends of €1.44 per preference share and €1.43 per ordinary share to shareholders from the retained profit.

Furthermore, the Executive Board submitted a Non-Financial Group Statement based on the German Law to Strengthen Companies' Non-Financial Reporting to implement the EU CSR Directive. The content of this statement was submitted to a voluntary review by KPMG AG Wirtschaftsprüfungsgesellschaft based on a limited assurance engagement. On the basis of this review, KPMG issued an unqualified opinion. The auditing company attended the Supervisory Board meeting on February 10, 2023, and reported on the results of its audit review. Following intensive discussions and examination, the Non-Financial Group Statement was also endorsed by the Supervisory Board members.

## Composition of the Supervisory Board and the Executive Board

In fiscal 2022, new elections were held for the shareholder and employee representatives on the Supervisory Board. On the shareholders' side, Professor Dr. Thomas Scheper, and on the employees' side, Karoline Kleinschmidt, both stepped down from the Supervisory Board at the end of the Annual General Meeting on March 25, 2022. We would like to thank Professor Scheper and Ms. Kleinschmidt for their many years of dedicated service on our Board. Frank Riemensperger and Sabrina Wirth from the Sartorius workforce were elected as their successors by the Annual General Meeting, and they took office at the Supervisory Board meeting on March 25, 2022. The other shareholder and employee representatives were all reelected. The composition of the Executive Board did not change in 2022.

We would like to express our sincere thanks to the Executive Board and all Sartorius employees worldwide for their extremely dedicated and successful work in the past fiscal year. We would also like to thank our shareholders for the confidence they have once again shown in the company.

Hamburg, February 2023

On Behalf of the Supervisory Board



Dr. Lothar Kappich

Chairman

# Sartorius Shares

## Downturn in Global Stock Markets

International stock markets recorded price declines the reporting year in the face of significant political and economic uncertainties. In addition to the war in Ukraine and the ongoing coronavirus pandemic, high inflation rates, rising interest rates, the slowdown in economic growth, and an increased risk of recession weighed on stock market sentiment. In this environment, almost all major benchmark indices experienced a downturn. The Dow Jones ended the year at 33,147 points and down 8.8%. The MSCI Europe closed out the year approximately 10.9% lower at 1,723 points. Germany's benchmark index DAX and the technology index TecDAX, which both include Sartorius preference shares, also posted losses of 12.3% to 13,924 points and 25.5% to 2,921 points, respectively.

## Price of Sartorius Shares Declines


The two classes of Sartorius AG shares, which generated significant gains in 2021, lost considerable ground in this market environment. Influencing factors included rising key interest rates, which led to capital outflows from the equity markets and weighed particularly heavily on the prices of growth and biotech stocks. In addition, investors faced a degree of uncertainty, particularly with regard to the short-term growth prospects of biopharma suppliers, triggered by the decline in pandemic-related business and the anticipated reduction in customer inventories. The company's preference share closed the 2022 stock-market year at €369.4 – down 37.9% year over year. The ordinary share closed around 33.0% lower at €334.5.

Sartorius AG preference shares have been listed in the German DAX share index since 2021, and are also included in the TecDAX. The preference shares ranked 33 in the DAX and 6th in the TecDAX at year-end based on the free float market capitalization criterion.


### Facts about the Shares

ISIN	DE0007165607 (ordinary shares)
	DE0007165631 (preference shares)
Designated sponsor	Oddo Seydler Bank AG   M.M. Warburg & Co. (AG & Co.) KGaA
Market segment	Prime Standard
Indexes	DAX   TecDAX   MSCI Germany Index   CDAX   Prime All Share-Index   Technology All Share-Index   NISAX20   STOXX Europe 600   DAX 50 ESG
Stock exchanges	XETRA   Frankfurt Main   Hanover   Hamburg   Berlin   Munich   Düsseldorf   Stuttgart   Tradegate
Number of shares	74,880,000 no-par individual share certificates with a calculated par value of €1 per share
Of which	37,440,000 ordinary shares
	37,440,000 preference shares
Of which shares outstanding	34,226,009 ordinary shares
	34,189,853 preference shares

**Sartorius Shares in €**  
January 1, 2018 to December 31, 2022



**Sartorius Shares in Comparison to DAX and MSCI Europe Index (indexed)**  
January 1, 2022 to December 31, 2022



Source: Nasdaq

## Market Capitalization and Trading Volume

The market capitalization of Sartorius AG based on the number of ordinary and preference shares outstanding fell in the reporting year by around 35.7% to €24.1 billion as of December 31, 2022, compared with €37.4 billion a year earlier.

The average number of preference shares traded daily on the Frankfurt Stock Exchange (Xetra and trading floor) was 89,710 during the reporting period, compared with 65,581 in the previous year. The trading volume was €8.9 billion (2021: €7.9 billion).

Due to the low free float of Sartorius' ordinary shares, they are traded only to a limited extent. Thus, the average number of ordinary shares traded daily was 5,070 compared with 4,244 in the previous year. The corresponding trading volume was around €433.5 million (2021: €577.7 million).

## Investor Relations

Sartorius, investor relations activities follow the objective of making the current and future development of the company transparent for its shareholders and other interested parties. To achieve this objective, Sartorius maintains an ongoing, open dialogue with shareholders, potential investors, and financial analysts.

Aside from providing quarterly, first-half, and annual reports, the company informs the capital market and the interested public at quarterly teleconferences and in regularly published press releases about the current development of the business and other material events at the company. Moreover, Group management and the IR team were available to communicate with capital market participants at conferences and roadshows. A virtual capital market tutorial was also held during the reporting year, in which the Group provided participants with in-depth information on specific product areas.

Further information and publications about the Sartorius Group and its shares are available online at [www.sartorius.com](http://www.sartorius.com).

## Analysts

The assessments and recommendations of financial analysts serve as an important foundation for the decisions of private and institutional investors when acquiring shares. During the reporting year, Sartorius maintained an ongoing dialogue with a total of 23 institutes.

### Research Coverage


Date	Institute	Price target in €	Recommendation
January 27, 2023	LBBW	500.00	Buy
January 27, 2023	M.M. Warburg	466.00	Buy
January 27, 2023	Société Générale	483.00	Hold
January 27, 2023	Metzler	588.00	Buy
January 27, 2023	J.P. Morgan	530.00	Buy
January 27, 2023	Eaxne BNP Paribas	440.00	Hold
January 26, 2023	UBS	460.00	Buy
January 26, 2023	SRH AlsterResearch	295.00	Sell
January 26, 2023	ODDO BHF	455.00	Buy
January 26, 2023	Morningstar	267.00	--
January 26, 2023	Morgan Stanley	465.00	Buy
January 26, 2023	KeyBanc	--	Hold
January 26, 2023	Kepler Cheuvreux	500.00	Buy
January 26, 2023	HSBC	350.00	Hold
January 26, 2023	Deutsche Bank	530.00	Buy
January 26, 2023	Berenberg	493.00	Buy
January 23, 2023	Credit Suisse	450.00	Hold
November 18, 2022	AlphaValue	474.00	Buy
October 20, 2022	EQUI.TS	--	Buy
October 20, 2022	DZ Bank	315.00	Hold
October 19, 2022	Bank of America Merrill Lynch	561.00	Buy
July 21, 2022	Stifel	500.00	Buy
February 10, 2022	Redburn	449.00	Buy

## Dividends

The total return generated by Sartorius shares has generally been based almost entirely on the positive development of the share price and only to a very small extent on dividend payments. In line with the rapid and highly innovation-driven development of the industry, the main focus of company's management is on successfully continuing on our dynamic profitable growth track and on making the extensive investments in capacity expansions, innovations and acquisitions that are constantly required for this purpose. Yet within this context, Sartorius strives to enable its shareholders to participate appropriately in the company's success through dividends.

The Executive Board and the Supervisory Board will submit a proposal to the Annual General Meeting on March 29, 2023, to pay dividends of €1.44 per preference share and €1.43 per ordinary share for fiscal 2022. If this proposal is approved, the total profit distributed would be €98.2 million, up 14.3% from the year-earlier sum of €85.9 million. The corresponding payout ratio lies within the general dividend policy, at 15.0% (previous year: 15.5%).

### Dividends in €



<sup>1</sup> The original dividend proposal of €0.71 per preference share and €0.70 per ordinary share was adjusted in light of the pandemic crisis

<sup>2</sup> Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG

## Total Shareholder Return

Total shareholder return (TSR) considers both the dividends paid out and any share price increases over a certain period, and thus reflects the entire performance of an investment. In 2021, Sartorius preference shares delivered a TSR of -37.7% (previous year: 73.4%), and its ordinary shares a TSR of -37.7% (previous year: 44.8%).


## Shareholder Structure

Sartorius AG's issued capital comprises 37,440,000 million ordinary shares and the same number of preference shares, each with a calculated par value of €1 per share. Some of both classes of share are held by the company itself. Minus these treasury shares, the number of ordinary shares outstanding is 34,226,009 and the number of preference shares outstanding is 34,189,853. A good 55% of the ordinary shares outstanding are under the management of an executor. According to the most recent information available, the U.S. company Bio-Rad Laboratories Inc. holds around 38% of the ordinary shares outstanding. To our knowledge, the remaining approximately 7% are in free float.


According to the information currently available, around 28% of the preference shares outstanding are held by Bio-Rad Laboratories Inc.; 72% are in free float.

**Shareholder Structure: Ordinary Shares**

in %, related to ~34.2 million shares outstanding

**Shareholder Structure: Preference Shares**

in %, related to ~34.2 million shares outstanding



Information on shareholdings and shares in free float pursuant to Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. Reporting obligations refer only to ordinary shares and not to non-voting preference shares.

**Key Figures for Sartorius Shares**

		2022	2021	2020	2019	2018
Ordinary shares <sup>1</sup> in €	Reporting date <sup>6</sup>	369.40	499.00	345.00	175.00	96.00
	High	595.20	827.00	362.00	176.00	139.00
	Low	302.40	329.00	156.50	92.60	76.80
Ordinary shares <sup>1</sup> in €	Reporting date <sup>6</sup>	334.50	595.20	343.60	190.80	108.90
	High	499.00	607.00	404.20	195.00	158.60
	Low	264.00	343.60	174.20	104.00	80.15
Market capitalization <sup>2</sup> in millions of €		24,078.3	37,428.6	23,555.6	12,507.9	7,006.1
Average daily trading volume of preference shares		89,710	65,581	80,572	65,810	107,761
Average daily trading volume of ordinary shares		5,070	4,244	2,774	1,238	2,153
Trading volume of preference shares in millions of €		8,932.3	7,949.1	5,937.9	2,682.6	3,571.1
Trading volume of ordinary shares in millions of €		433.5	577.7	179.6	45.7	61.3
Total trading volume in millions of €		9,365.8	8,526.8	6,117.6	2,728.3	3,632.4
Dividend per ordinary share <sup>3</sup> in €		1.43	1.25	0.70	0.35	0.61
Dividend per preference share <sup>3</sup> in €		1.44	1.26	0.71	0.36	0.62
Total dividends <sup>3, 4</sup> in millions of €		85.9	85.9	48.2	24.3	42.1
Dividend yield per ordinary share <sup>5</sup> in %		0.4	0.3	0.2	0.2	0.6
Dividend yield per preference share <sup>5</sup> in %		0.4	0.2	0.2	0.2	0.6

1 Xetra daily closing price

2 Without treasury shares

3 For 2022, amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG

4 Calculated on the basis of the number of shares entitled to dividends

5 In relation to the closing price in the year concerned

6 As of December 31 of the respective year

Sources: NASDAQ, Bloomberg